Review Article
Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
Table 1
Design of the six main randomized trials of etravirine.
| Trial [ref] | Treatment arms | Inclusion | Duration | Primary endpoint |
| DUET [26, 27] | BR + ETR | Experienced | 96 weeks | HIV RNA <50 c/mL | BR + placebo |
|
SENSE [28] | 2NRTI + ETR | Naïve | 48 weeks | CNS adverse events | 2NRTI + EFV |
|
UK SSAT029 [29] | 2NRTI + ETR | HIV RNA <50 | 24 weeks | CNS adverse events | 2NRTI + EFV |
|
Swiss SWITCH-EE [30] | 2NRTI + ETR | HIV RNA <50 | 12 weeks | Patient satisfaction | 2NRTI + EFV |
|
ETRA-SWITCH [31] | 2NRTI + ETR | HIV RNA <50 | 48 weeks | HIV RNA <50 c/mL | 2NRTI + PI/r |
|
|